Literature DB >> 22826388

Molecular imaging of prostate cancer: PET radiotracers.

Hossein Jadvar1.   

Abstract

OBJECTIVE: Recent advances in the fundamental understanding of the complex biology of prostate cancer have provided an increasing number of potential targets for imaging and treatment. The imaging evaluation of prostate cancer needs to be tailored to the various phases of this remarkably heterogeneous disease.
CONCLUSION: In this article, I review the current state of affairs on a range of PET radiotracers for potential use in the imaging evaluation of men with prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22826388      PMCID： PMC3408965          DOI： 10.2214/AJR.12.8816

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN： 0361-803X            Impact factor:   3.959


  214 in total

1.  Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.

Authors:  Masato Shiiba; Keiichi Ishihara; Go Kimura; Tomoyuki Kuwako; Hisashi Yoshihara; Naohisa Yoshihara; Hidetaka Sato; Yukihiro Kondo; Shin-ichi Tsuchiya; Shin-ichiro Kumita
Journal:  Ann Nucl Med       Date:  2011-11-09       Impact factor: 2.668

2.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.

Authors:  David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

3.  Design, synthesis and validation of integrin α2β1-targeted probe for microPET imaging of prostate cancer.

Authors:  Chiun-Wei Huang; Zibo Li; Hancheng Cai; Kai Chen; Tony Shahinian; Peter S Conti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-25       Impact factor: 9.236

4.  68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.

Authors:  Sangeeta Ray Banerjee; Mrudula Pullambhatla; Youngjoo Byun; Sridhar Nimmagadda; Gilbert Green; James J Fox; Andrew Horti; Ronnie C Mease; Martin G Pomper
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

5.  18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate.

Authors:  Datta E Ponde; Carmen S Dence; Nobuyuki Oyama; Joonyoung Kim; Yuan-Chuan Tai; Richard Laforest; Barry A Siegel; Michael J Welch
Journal:  J Nucl Med       Date:  2007-03       Impact factor: 10.057

6.  89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

Authors:  Jason P Holland; Vadim Divilov; Neil H Bander; Peter M Smith-Jones; Steven M Larson; Jason S Lewis
Journal:  J Nucl Med       Date:  2010-07-21       Impact factor: 10.057

7.  Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors.

Authors:  Jeffrey V Leyton; Tove Olafsen; Mark A Sherman; Karl B Bauer; Patrick Aghajanian; Robert E Reiter; Anna M Wu
Journal:  Protein Eng Des Sel       Date:  2008-10-28       Impact factor: 1.650

Review 8.  The role of DNA synthesis imaging in cancer in the era of targeted therapeutics.

Authors:  Sridhar Nimmagadda; Anthony F Shields
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

9.  Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors.

Authors:  Jeffrey V Leyton; Tove Olafsen; Eric J Lepin; Scott Hahm; Karl B Bauer; Robert E Reiter; Anna M Wu
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

10.  Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Wolfgang Loidl; Gabriele Broinger; Franz Stoiber; Ignac Foglman; Werner Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236
View more
  37 in total

1.  Writing PET into existence.

Authors:  A Chiti; M Kirienko; E Incerti; M Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236

2.  Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  Clin Transl Imaging       Date:  2017-04-10

3.  Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT.

Authors:  Hossein Jadvar; Erik M Velez; Bhushan Desai; Lingyun Ji; Patrick M Colletti; David I Quinn
Journal:  J Nucl Med       Date:  2019-03-29       Impact factor: 10.057

4.  Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.

Authors:  Chung Yao Yu; Bhushan Desai; Lingyun Ji; Susan Groshen; Hossein Jadvar
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-09-06

Review 5.  Prognostic Utility of PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2015-01-22

Review 6.  Is There Use for FDG-PET in Prostate Cancer?

Authors:  Hossein Jadvar
Journal:  Semin Nucl Med       Date:  2016-09-03       Impact factor: 4.446

7.  Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.

Authors:  Yong-Il Kim; Gi Jeong Cheon; Jin Chul Paeng; Jeong Yeon Cho; Cheol Kwak; Keon Wook Kang; June-Key Chung; Euishin Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-11       Impact factor: 9.236

Review 8.  Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations.

Authors:  Hossein Jadvar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-22       Impact factor: 9.236

Review 9.  Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.

Authors:  Hossein Jadvar
Journal:  Abdom Radiol (NY)       Date:  2016-05

Review 10.  Current Status of Hybrid PET/MRI in Oncologic Imaging.

Authors:  Andrew B Rosenkrantz; Kent Friedman; Hersh Chandarana; Amy Melsaether; Linda Moy; Yu-Shin Ding; Komal Jhaveri; Luis Beltran; Rajan Jain
Journal:  AJR Am J Roentgenol       Date:  2015-10-22       Impact factor: 3.959
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.